Cargando…
Large-scale analyses of CAV1 and CAV2 suggest their expression is higher in post-mortem ALS brain tissue and affects survival
Introduction: Caveolin-1 and Caveolin-2 (CAV1 and CAV2) are proteins associated with intercellular neurotrophic signalling. There is converging evidence that CAV1 and CAV2 (CAV1/2) genes have a role in amyotrophic lateral sclerosis (ALS). Disease-associated variants have been identified within CAV1/...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017967/ https://www.ncbi.nlm.nih.gov/pubmed/36937187 http://dx.doi.org/10.3389/fncel.2023.1112405 |
_version_ | 1784907708215853056 |
---|---|
author | Adey, Brett N. Cooper-Knock, Johnathan Al Khleifat, Ahmad Fogh, Isabella van Damme, Philip Corcia, Philippe Couratier, Philippe Hardiman, Orla McLaughlin, Russell Gotkine, Marc Drory, Vivian Silani, Vincenzo Ticozzi, Nicola Veldink, Jan H. van den Berg, Leonard H. de Carvalho, Mamede Pinto, Susana Mora Pardina, Jesus S. Povedano Panades, Mónica Andersen, Peter M. Weber, Markus Başak, Nazli A. Shaw, Christopher E. Shaw, Pamela J. Morrison, Karen E. Landers, John E. Glass, Jonathan D. Vourc’h, Patrick Dobson, Richard J. B. Breen, Gerome Al-Chalabi, Ammar Jones, Ashley R. Iacoangeli, Alfredo |
author_facet | Adey, Brett N. Cooper-Knock, Johnathan Al Khleifat, Ahmad Fogh, Isabella van Damme, Philip Corcia, Philippe Couratier, Philippe Hardiman, Orla McLaughlin, Russell Gotkine, Marc Drory, Vivian Silani, Vincenzo Ticozzi, Nicola Veldink, Jan H. van den Berg, Leonard H. de Carvalho, Mamede Pinto, Susana Mora Pardina, Jesus S. Povedano Panades, Mónica Andersen, Peter M. Weber, Markus Başak, Nazli A. Shaw, Christopher E. Shaw, Pamela J. Morrison, Karen E. Landers, John E. Glass, Jonathan D. Vourc’h, Patrick Dobson, Richard J. B. Breen, Gerome Al-Chalabi, Ammar Jones, Ashley R. Iacoangeli, Alfredo |
author_sort | Adey, Brett N. |
collection | PubMed |
description | Introduction: Caveolin-1 and Caveolin-2 (CAV1 and CAV2) are proteins associated with intercellular neurotrophic signalling. There is converging evidence that CAV1 and CAV2 (CAV1/2) genes have a role in amyotrophic lateral sclerosis (ALS). Disease-associated variants have been identified within CAV1/2 enhancers, which reduce gene expression and lead to disruption of membrane lipid rafts. Methods: Using large ALS whole-genome sequencing and post-mortem RNA sequencing datasets (5,987 and 365 tissue samples, respectively), and iPSC-derived motor neurons from 55 individuals, we investigated the role of CAV1/2 expression and enhancer variants in the ALS phenotype. Results: We report a differential expression analysis between ALS cases and controls for CAV1 and CAV2 genes across various post-mortem brain tissues and three independent datasets. CAV1 and CAV2 expression was consistently higher in ALS patients compared to controls, with significant results across the primary motor cortex, lateral motor cortex, and cerebellum. We also identify increased survival among carriers of CAV1/2 enhancer mutations compared to non-carriers within Project MinE and slower progression as measured by the ALSFRS. Carriers showed a median increase in survival of 345 days. Discussion: These results add to an increasing body of evidence linking CAV1 and CAV2 genes to ALS. We propose that carriers of CAV1/2 enhancer mutations may be conceptualised as an ALS subtype who present a less severe ALS phenotype with a longer survival duration and slower progression. Upregulation of CAV1/2 genes in ALS cases may indicate a causal pathway or a compensatory mechanism. Given prior research supporting the beneficial role of CAV1/2 expression in ALS patients, we consider a compensatory mechanism to better fit the available evidence, although further investigation into the biological pathways associated with CAV1/2 is needed to support this conclusion. |
format | Online Article Text |
id | pubmed-10017967 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100179672023-03-17 Large-scale analyses of CAV1 and CAV2 suggest their expression is higher in post-mortem ALS brain tissue and affects survival Adey, Brett N. Cooper-Knock, Johnathan Al Khleifat, Ahmad Fogh, Isabella van Damme, Philip Corcia, Philippe Couratier, Philippe Hardiman, Orla McLaughlin, Russell Gotkine, Marc Drory, Vivian Silani, Vincenzo Ticozzi, Nicola Veldink, Jan H. van den Berg, Leonard H. de Carvalho, Mamede Pinto, Susana Mora Pardina, Jesus S. Povedano Panades, Mónica Andersen, Peter M. Weber, Markus Başak, Nazli A. Shaw, Christopher E. Shaw, Pamela J. Morrison, Karen E. Landers, John E. Glass, Jonathan D. Vourc’h, Patrick Dobson, Richard J. B. Breen, Gerome Al-Chalabi, Ammar Jones, Ashley R. Iacoangeli, Alfredo Front Cell Neurosci Cellular Neuroscience Introduction: Caveolin-1 and Caveolin-2 (CAV1 and CAV2) are proteins associated with intercellular neurotrophic signalling. There is converging evidence that CAV1 and CAV2 (CAV1/2) genes have a role in amyotrophic lateral sclerosis (ALS). Disease-associated variants have been identified within CAV1/2 enhancers, which reduce gene expression and lead to disruption of membrane lipid rafts. Methods: Using large ALS whole-genome sequencing and post-mortem RNA sequencing datasets (5,987 and 365 tissue samples, respectively), and iPSC-derived motor neurons from 55 individuals, we investigated the role of CAV1/2 expression and enhancer variants in the ALS phenotype. Results: We report a differential expression analysis between ALS cases and controls for CAV1 and CAV2 genes across various post-mortem brain tissues and three independent datasets. CAV1 and CAV2 expression was consistently higher in ALS patients compared to controls, with significant results across the primary motor cortex, lateral motor cortex, and cerebellum. We also identify increased survival among carriers of CAV1/2 enhancer mutations compared to non-carriers within Project MinE and slower progression as measured by the ALSFRS. Carriers showed a median increase in survival of 345 days. Discussion: These results add to an increasing body of evidence linking CAV1 and CAV2 genes to ALS. We propose that carriers of CAV1/2 enhancer mutations may be conceptualised as an ALS subtype who present a less severe ALS phenotype with a longer survival duration and slower progression. Upregulation of CAV1/2 genes in ALS cases may indicate a causal pathway or a compensatory mechanism. Given prior research supporting the beneficial role of CAV1/2 expression in ALS patients, we consider a compensatory mechanism to better fit the available evidence, although further investigation into the biological pathways associated with CAV1/2 is needed to support this conclusion. Frontiers Media S.A. 2023-03-02 /pmc/articles/PMC10017967/ /pubmed/36937187 http://dx.doi.org/10.3389/fncel.2023.1112405 Text en Copyright © 2023 Adey, Cooper-Knock, Al Khleifat, Fogh, van Damme, Corcia, Couratier, Hardiman, McLaughlin, Gotkine, Drory, Silani, Ticozzi, Veldink, van den Berg, de Carvalho, Pinto, Mora Pardina, Povedano Panades, Andersen, Weber, Başak, Shaw, Shaw, Morrison, Landers, Glass, Vourc’h, Dobson, Breen, Al-Chalabi, Jones and Iacoangeli. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cellular Neuroscience Adey, Brett N. Cooper-Knock, Johnathan Al Khleifat, Ahmad Fogh, Isabella van Damme, Philip Corcia, Philippe Couratier, Philippe Hardiman, Orla McLaughlin, Russell Gotkine, Marc Drory, Vivian Silani, Vincenzo Ticozzi, Nicola Veldink, Jan H. van den Berg, Leonard H. de Carvalho, Mamede Pinto, Susana Mora Pardina, Jesus S. Povedano Panades, Mónica Andersen, Peter M. Weber, Markus Başak, Nazli A. Shaw, Christopher E. Shaw, Pamela J. Morrison, Karen E. Landers, John E. Glass, Jonathan D. Vourc’h, Patrick Dobson, Richard J. B. Breen, Gerome Al-Chalabi, Ammar Jones, Ashley R. Iacoangeli, Alfredo Large-scale analyses of CAV1 and CAV2 suggest their expression is higher in post-mortem ALS brain tissue and affects survival |
title | Large-scale analyses of CAV1 and CAV2 suggest their expression is higher in post-mortem ALS brain tissue and affects survival |
title_full | Large-scale analyses of CAV1 and CAV2 suggest their expression is higher in post-mortem ALS brain tissue and affects survival |
title_fullStr | Large-scale analyses of CAV1 and CAV2 suggest their expression is higher in post-mortem ALS brain tissue and affects survival |
title_full_unstemmed | Large-scale analyses of CAV1 and CAV2 suggest their expression is higher in post-mortem ALS brain tissue and affects survival |
title_short | Large-scale analyses of CAV1 and CAV2 suggest their expression is higher in post-mortem ALS brain tissue and affects survival |
title_sort | large-scale analyses of cav1 and cav2 suggest their expression is higher in post-mortem als brain tissue and affects survival |
topic | Cellular Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017967/ https://www.ncbi.nlm.nih.gov/pubmed/36937187 http://dx.doi.org/10.3389/fncel.2023.1112405 |
work_keys_str_mv | AT adeybrettn largescaleanalysesofcav1andcav2suggesttheirexpressionishigherinpostmortemalsbraintissueandaffectssurvival AT cooperknockjohnathan largescaleanalysesofcav1andcav2suggesttheirexpressionishigherinpostmortemalsbraintissueandaffectssurvival AT alkhleifatahmad largescaleanalysesofcav1andcav2suggesttheirexpressionishigherinpostmortemalsbraintissueandaffectssurvival AT foghisabella largescaleanalysesofcav1andcav2suggesttheirexpressionishigherinpostmortemalsbraintissueandaffectssurvival AT vandammephilip largescaleanalysesofcav1andcav2suggesttheirexpressionishigherinpostmortemalsbraintissueandaffectssurvival AT corciaphilippe largescaleanalysesofcav1andcav2suggesttheirexpressionishigherinpostmortemalsbraintissueandaffectssurvival AT couratierphilippe largescaleanalysesofcav1andcav2suggesttheirexpressionishigherinpostmortemalsbraintissueandaffectssurvival AT hardimanorla largescaleanalysesofcav1andcav2suggesttheirexpressionishigherinpostmortemalsbraintissueandaffectssurvival AT mclaughlinrussell largescaleanalysesofcav1andcav2suggesttheirexpressionishigherinpostmortemalsbraintissueandaffectssurvival AT gotkinemarc largescaleanalysesofcav1andcav2suggesttheirexpressionishigherinpostmortemalsbraintissueandaffectssurvival AT droryvivian largescaleanalysesofcav1andcav2suggesttheirexpressionishigherinpostmortemalsbraintissueandaffectssurvival AT silanivincenzo largescaleanalysesofcav1andcav2suggesttheirexpressionishigherinpostmortemalsbraintissueandaffectssurvival AT ticozzinicola largescaleanalysesofcav1andcav2suggesttheirexpressionishigherinpostmortemalsbraintissueandaffectssurvival AT veldinkjanh largescaleanalysesofcav1andcav2suggesttheirexpressionishigherinpostmortemalsbraintissueandaffectssurvival AT vandenbergleonardh largescaleanalysesofcav1andcav2suggesttheirexpressionishigherinpostmortemalsbraintissueandaffectssurvival AT decarvalhomamede largescaleanalysesofcav1andcav2suggesttheirexpressionishigherinpostmortemalsbraintissueandaffectssurvival AT pintosusana largescaleanalysesofcav1andcav2suggesttheirexpressionishigherinpostmortemalsbraintissueandaffectssurvival AT morapardinajesuss largescaleanalysesofcav1andcav2suggesttheirexpressionishigherinpostmortemalsbraintissueandaffectssurvival AT povedanopanadesmonica largescaleanalysesofcav1andcav2suggesttheirexpressionishigherinpostmortemalsbraintissueandaffectssurvival AT andersenpeterm largescaleanalysesofcav1andcav2suggesttheirexpressionishigherinpostmortemalsbraintissueandaffectssurvival AT webermarkus largescaleanalysesofcav1andcav2suggesttheirexpressionishigherinpostmortemalsbraintissueandaffectssurvival AT basaknazlia largescaleanalysesofcav1andcav2suggesttheirexpressionishigherinpostmortemalsbraintissueandaffectssurvival AT shawchristophere largescaleanalysesofcav1andcav2suggesttheirexpressionishigherinpostmortemalsbraintissueandaffectssurvival AT shawpamelaj largescaleanalysesofcav1andcav2suggesttheirexpressionishigherinpostmortemalsbraintissueandaffectssurvival AT morrisonkarene largescaleanalysesofcav1andcav2suggesttheirexpressionishigherinpostmortemalsbraintissueandaffectssurvival AT landersjohne largescaleanalysesofcav1andcav2suggesttheirexpressionishigherinpostmortemalsbraintissueandaffectssurvival AT glassjonathand largescaleanalysesofcav1andcav2suggesttheirexpressionishigherinpostmortemalsbraintissueandaffectssurvival AT vourchpatrick largescaleanalysesofcav1andcav2suggesttheirexpressionishigherinpostmortemalsbraintissueandaffectssurvival AT dobsonrichardjb largescaleanalysesofcav1andcav2suggesttheirexpressionishigherinpostmortemalsbraintissueandaffectssurvival AT breengerome largescaleanalysesofcav1andcav2suggesttheirexpressionishigherinpostmortemalsbraintissueandaffectssurvival AT alchalabiammar largescaleanalysesofcav1andcav2suggesttheirexpressionishigherinpostmortemalsbraintissueandaffectssurvival AT jonesashleyr largescaleanalysesofcav1andcav2suggesttheirexpressionishigherinpostmortemalsbraintissueandaffectssurvival AT iacoangelialfredo largescaleanalysesofcav1andcav2suggesttheirexpressionishigherinpostmortemalsbraintissueandaffectssurvival |